MedPath

EVERIMMUNE

🇫🇷France
Ownership
-
Employees
-
Market Cap
-
Website

A Study of Oncobax®-AK in Patients With Advanced Solid Tumors

Phase 2
Recruiting
Conditions
Carcinoma, Renal Cell
Carcinoma, Non-Small-Cell Lung
Interventions
Other: Live Bacterial Product - Akkermansia muciniphila
First Posted Date
2023-05-19
Last Posted Date
2023-05-19
Lead Sponsor
EverImmune
Target Recruit Count
122
Registration Number
NCT05865730
Locations
🇧🇪

CHU Ambroise Paré, Mons, Belgium

🇫🇷

Centre Georges Francois Leclerc, Dijon, France

🇫🇷

Institut Gustave Roussy, Paris, France

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath